Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC – OncLive
OncLive |
Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC
OncLive It is estimated that one-quarter of patients with non–small cell lung cancer (NSCLC) will present with stage III disease at diagnosis, but the population rarely receives attention in the clinical trial space, says David R. Spigel, MD. There have been … |
